Mapi Research Trust recently launched it's 3rd version of PROQOLID, the world’s largest and most widely used database dedicated to Clinical Outcome Assessments (COAs).
Oncology Market Access (OMA) U.S. provides strategic and tactical insights into the evolving oncology landscape. Combining Kantar Health’s commercial and clinical expertise in oncology, OMA U.S. provides cutting-edge information and analysis on critical reimbursement, coverage and competitive issues in the U.S. oncology marketplace. This subscription helps pharmaceutical marketing and sales professionals more successfully position cancer drugs in an increasingly scrutinized and regulated oncology marketplace. The analyses are based on industry experience augmented by in-depth research with key stakeholders, including oncologists, payers, practice managers, patients and subject matter experts. From Kantar Health
Oncology Market Access Europe is a web-resident source of information and insight and access to experts. It provides cutting-edge information and analysis on critical reimbursement, coverage, and competitive issues in the EU oncology landscape. This subscription helps pharmaceutical marketing and sales professionals more successfully position cancer drugs in an increasingly scrutinized and regulated oncology marketplace. The analyses are based on industry experience augmented by in-depth research with key stakeholders, including oncologists, payers and subject matter experts.
Model Transparency and Validation: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7
Dynamic Transmission Modeling: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-5
2011 benchmarking database from IBI, including 62,000 employers with 3.5 million claims, 972 industries from 13 major data provides. Also includes comparisons by state/geographic location for disability, analysis by claim year in workers' comp, and entirely new FMLA reporting metrics.
Presentation at ISPOR Europe, Nov. 2011, by Daniel Huse, MA, Vice President, Thomson Reuters, Cambridge, MA, USA
Presentation at ISPOR Europe, Nov. 2011, by Robert J. LoCasale, PhD, MS, Senior Epidemiologist, Epidemiology, Merck, North Wales, PA, USA
The document provides a survey of the current processes on data availability during relative effectiveness assessments at national level. It highlights a number of key findings and best practices. Lastly the document contains some possible recommendations for the future.
Linda S Deal, MS, Head, Health Outcomes, eResearch Technology Inc, Philadelphia, PA, USA; Paul O'Donohoe, BSc, Manager of Health Outcomes, CRF Health, London, UK; Jean Paty, PhD, Chief Scientist and Regulatory Officer, PRO Consulting, Invivodata Ltd., Pittsburgh, PA, USA; Diane Wild, MSc, Vice President, ePRO and Translations, Oxford Outcomes Ltd., an ICON PLC Company, Oxford, Oxon, UK, ISPOR Washington DC, 2012.
The MABEL survey is a longitudinal panel survey of Australian doctors launched in 2008 aimed at investigating doctors' workforce participation patterns and their determinants. The second data release is now available.
The National Patient Advocate Foundation has launched a comparative-effectiveness research database (PDF) that compiles research funded by the National Institutes of Health and the Agency for Healthcare Research and Quality...The database was launched with information on 224 NIH research projects; a separate database catalogs information on 49 cancer-related comparative-effective research projects funded through the NIH...Also included in the database is information on 352 AHRQ research projects, 72 of which were paid for with stimulus funds. (Source: (1/6, Andis Robeznieks, Modern Physician)
RxEOB’s RxEConnect allows health plan users to use pharmacy claims data to generate personalized communications, including cost-savings opportunities, care alerts, drug-migration, health program recruitment, as well as EOBs and TrOOP reports.
RxSentinel, from RxEOB, is a suite of health plan branded web-applications and supporting APIs that allows pharmacy data, and the insights generated from it, to meet the informational needs of external stakeholders
RxMonitor, from RxEOB, allows health plans to unleash the power of Pharmacy Business Intelligence. The solution is an analytic and reporting engine for gleaning insights from pharmacy data to meet the unique informatics needs of all stakeholders.
Health Systems Evidence is a continuously updated repository of syntheses of research evidence about governance, financial and delivery arrangements within health systems, and about implementation strategies that can support change in health systems.
How to produce national and regional estimates by weighing the unweighted HCUP data (e-news, Issue #24).
The Standard Analytical Files (SAFs) contain information collected by Medicare to pay for health care services provided to a Medicare beneficiary. SAFs are available for each institutional (inpatient, outpatient, skilled nursing facility, hospice, or home health agency) and non-institutional (physician and durable medical equipment providers) claim type. The record unit of SAFs is the claim (some episodes of care may have more than one claim).
Electronic index (digest) of 325 databases from 45 countries. The Digest consists of key attributes of health care databases. It is grouped by country and allows both key word searches and searches by type of database.
DIRUM is a practical, open-access database of resource-use questionnaires for use by trial health economists.
The CAHPS Database is the national repository for data from selected CAHPS surveys. The online reporting system contains comparative data for the CAHPS Health Plan (HP) Survey and the CAHPS Clinician & Group (CG) Survey.
Epi Database® is the gold standard of epidemiology data, providing reliable, rigorous research and documentation in the G7 (U.S., Japan, France, Germany, Italy, Spain, UK) and key emerging countries (Brazil, China, India, Mexico, Russia, Turkey). Epi Database® offers unsurpassed breadth of coverage with up to 190 indications, over 1,000 subindications and up to 19 therapeutic areas. From Kantar Health.